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ABSTRACT
Introduction: This study provided physicians
with continuing medical education (CME)
related to type 2 diabetes and evaluated the
effect on patient health outcomes.
Methods: Physicians participated in
multi-platform CME (live and online
programs) and completed a 25 item
questionnaire for patient baseline (3-months
pre-CME activity) and follow-up visits
(C6-months post-CME activity). Changes in
physician knowledge and patient health
outcomes were evaluated.
Results: 34 physicians completed both phases
of the CME curricula and submitted data for 264
patients. Significant improvements were
observed in physician knowledge after the live
(p\0.05) and online programs (p\0.0005).
Mean patient glycated hemoglobin (HbA1c)
absolute reduction of 1.15% (p\0.0001) was
reported.
Conclusions: CME is an effective tool to close
established practice gaps and potentially help
improve patient health outcomes.
Keywords: Continuing medical education;
Diabetes mellitus; Management of T2DM;
Type-2 diabetes
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a highly
prevalent and serious chronic, debilitating
disease. Extensive evidence exists for the
benefit of maintaining tight glycemic control
to reduce the risk for complications. Despite
this evidence, many patients do not maintain
tight glycemic control with one reason being
clinical inertia [1]. Clinical inertia is the failure
to intensify therapy despite suboptimal
glycemic control. Implementation of
educational programs that emphasize the
importance of glycemic control and increase
awareness of tools to achieve this control
among primary care physicians may be an
important factor in devising successful
treatment regimens that result in improved
outcomes [1]. The ultimate goal of continuing
medical education (CME) is to transfer learned
knowledge, competence, and performance
related skills into the practice setting [2].
Improvements in patient health outcomes
may indicate whether or not physician
participation in CME activities was effective in
modifying clinical practice patterns. Research
evaluating CME effectiveness has indicated that
multiple educational platforms and case-based
studies are more successful than the traditional
didactic sessions alone at improving patient
health outcomes [3, 4]. Several key factors for
improving T2DM management include realistic
goal-setting related to glycated hemoglobin
(Hb1Ac) levels, improved knowledge and
understanding of pharmacotherapeutic
treatment options, early detection of
problems, and prompt clinical intervention
[1]. One aim of this study was to provide
physicians with education specific to insulin
to implement changes in their delivery of care
to patients with T2DM. To address this, a
combined live didactic session and online
case-based interactive diabetes CME curricula
were developed. The effectiveness of the CME
program on physician knowledge, competence,
and performance outcomes was assessed [2]. In
addition, the impact of the curricula on changes
in physician behavior in the clinical practice
was assessed by measuring patient health
outcomes before and after the CME activities.
METHODS
Continuing Medical Education Curricula
and Time Line
Multiple platform CME curricula were jointly
developed by six US endocrinology experts
actively engaged in diabetes clinical research
and education, who served as program faculty.
The target learning audience for these curricula
was primary care physicians. The
multi-platform curricula included a live
didactic session as well as interactive online
case-based sessions. The first live didactic
session consisted of a 90-min slide
presentation entitled: ‘‘Overcoming Challenges
in Treatment Intensification for Type 2
Diabetes.’’ Physician learners attended 1 of 7
identical live CME activities occurring at
different sites across the US from February to
December 2012 and/or an online 12 month
enduring webcast featuring the same
presentation as the live sessions. Physician
learners participated in a second online
interactive case-based activity (choice of two
individual patient cases), which was available 4
weeks after the live session, between March
2012 and January 2013. The online case-based
activity session was algorithmically tailored to
each learner based on the education gaps
identified from the activity questions
following the live CME event. Activity
questions were based around the objectives of
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the educational activity and designed to
measure the extent to which the established
educational gaps for each individual clinician
were met at the completion of the live activity.
Clinicians were offered participation in one or
both of the online case studies based on scores
they achieved following the live CME event.
The CME curricula were designed with the
following learning objectives:
1. Apply current data from clinical trials for
HbA1C goal-setting and individualization
of treatment.
2. Recognize the importance of timely
initiation of drug therapy including early
insulin initiation in reducing the
complications of T2DM.
3. Identify and implement strategies for
overcoming barriers to insulin initiation
and patient medication adherence.
4. Describe interdisciplinary team and
collaborative care approaches that can
improve patient health outcomes.
Patient Chart Review
Following each live event, all attendees were
sent an email invitation to participate in the
patient chart questionnaire portion of the
study, to retrospectively assess the impact of
the CME on learner performance and patient
health outcomes (Level 5 and Level 6 of Moore’s
Framework). Patient chart review data
collection occurred between July 2012 and
December 2013. Physician participation
consisted of completing a 25 item
questionnaire for up to 15 patients, selected at
the physician’s discretion, who met the
inclusion criteria. Patient inclusion criteria
included the following: C18 years of age, body
mass index B40, T2DM diagnosis B10 years, no
initiation of insulin therapy prior to the
baseline visit, and a baseline HbA1c level
C8.0%.
Physicians completed patient chart audit
questionnaires based on clinical visits at two
separate points in time (baseline and
follow-up). Physicians completed
questionnaires for baseline visits occurring
within 3 months prior to the attended live
CME event. If a patient had more than one
office visit during the 3-month baseline period,
the most recent visit was used for the
completion of the questionnaire. Physicians
also completed a follow-up questionnaire for
visits occurring within 6 months after the live
CME event. If more than one visit occurred
during the 6-month follow-up period, then the
last visit during the 6-month period was used
for the chart review, since the HbA1c
measurement there represents the final HbA1c
in the follow-up period. Institutional Review
Board approval was not required, since patient
identifiable information was not collected, and
the observational data were used solely for
quality improvement purposes.
Assessment of Physician Learner
Performance and Patient Health
Outcomes
Improvement in physician learner performance
and patient health outcomes were evaluated
based on Moore’s framework outcome levels
1–6 [2], which were evaluated through the
following means:
• Pre- and post-activity surveys to measure
baseline and immediate changes in
declarative (level 3A) and procedural
knowledge (level 3B)
• 30 to 60-day follow-up survey to measure
impact on clinical decision making and
changes in practice (levels 5)
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• Patient chart review to measure impact
on clinical decision making and the
resultant patient health outcomes (levels
5 and 6)
Statistical Analysis
Data on physician learner performance, along
with patient chart review data from the baseline
and follow-up visit questionnaires, were entered
into an Excel-based study report form. Patient
health outcome study endpoints included mean
reduction in HbA1c, percent of patients with an
HbA1c reduction of C0.5%, percent of patients
initiating insulin therapy, percent of patients
reaching HbA1c goal B7.0%, and the
percentage of patients, whose therapy was
intensified (overcoming clinical inertia).
Descriptive univariate statistics, including
mean and standard deviation (SD), were
provided for continuous variables; count and
percentage were provided for categorical
variables. Paired student t test was used to
evaluate the change in the mean patient
HbA1c values from baseline measurements to
the follow-up measurements after the CME
program. Statistical data analyses were
conducted using SAS 9.2 (SAS institute, Cary,
North Carolina, USA).
RESULTS
Summary of Physician Participation
in CME Activities and Patient
Chart Review
A total of 4112 primary care physicians attended
1 of 7 identical CME live programs on T2DM
between February and December 2012 (Table 1).
Of these, 445 replied with interest in the study,
and 34 of 445 physicians completed both phases
(live program and online case-based study) of
the CME curricula. These physicians submitted
264 patient chart review forms (Table 1). Table 1
lists a breakdown of the number of patient
charts submitted per physician as well as the
number of participating physicians from each
live CME site.
Physician Learner Knowledge,
Competence and Performance Scores
A summary of physician learner pre- and
post-CME mean test scores for outcomes













Feb. 9, 2012 658 80 5 1, 1, 9, 12, 4 = 27
Mar. 10, 2012 523 99 7 9, 5, 6, 11, 3, 4, 5 = 43
April 11, 2012 918 69 7 4, 13, 3, 10, 7, 15, 17 = 69
June 23, 2012 548 75 8 1, 2, 10, 1, 5, 10, 13, 15 = 57
Sept. 19, 2012 510 54 3 15, 2, 5 = 22
Nov. 15, 2012 492 35 4 5, 7, 1, 33 = 46
Dec. 8, 2012 463 33 0 0
CME continuing medical education
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related to knowledge, competence, and
performance (Moore’s framework levels 3, 4,
and 5, respectively) is presented in Table 2. For
the didactic live session, significant
improvements in performance related
outcomes were observed for all live sites
(p\0.05) with significance reaching p\0.0005
for the online version of the same presentation
(Table 2). Competence outcome scores were
significantly higher post-CME for all sites
except New York and Boston (Table 2).
Knowledge outcome scores significantly
improved post-CME for all sites except New
York (Table 2). For the interactive case-based
studies, knowledge significantly improved
(p\0.0005) for most categories (Table 2).
Patient Health Baseline Characteristics
and Outcomes
Table 3 summarizes mean baseline
characteristics captured in the patient
chart reviews. Patient chart reviews were
completed for 264 patients, of which 51.89%
(n = 137) were male. The mean age of patients
was 53.98 years (SD = 13.06). The mean
duration of T2DM disease was 4.62 years. The
mean HbA1c level at baseline was 9.37%
(SD = 1.62%), and only 3.41% of patients
(n = 9) had a baseline HbA1c level B7.0%.
Improvements in patient health outcomes
were observed in the follow-up period when
comparing patient data captured in the
follow-up chart reviews to the baseline patient
data. The mean reduction in Hb1Ac levels and
additional use of anti-diabetic medications were
the primary endpoints measured for assessing
patient health outcomes. Figure 1 illustrates a
comparison of the mean Hb1Ac levels observed
at the follow-up (8.22%; SD = 1.60%) and
baseline (9.37%; SD = 1.62%) visits. A mean
patient HbA1c absolute reduction of 1.15%
(p\0.0001) was observed in the follow-up
period (Fig. 1). Table 4 lists additional
endpoint results for patient health outcomes.
44.3% (n = 117) of patients initiated insulin
therapy between the baseline and follow-up
period. 64.4% percent (n = 170) of patients had
a reduction in HbA1c levels of at least 0.5%
(Table 4). 20.3% of patients (n = 50) had a mean
HbA1c level B7.0% in the follow-up period
compared to 3.41% of patients prior to the CME
activities (baseline) (p\0.0001). In addition,
therapy was intensified for 75% of patients
(n = 197) in the follow-up period.
DISCUSSION
Data from this study suggest that there is a
potentially positive relationship between
physician participation in a multiple platform
CME curriculum and improvements in the
outcomes of patients with T2DM. Significant
improvements (p\0.0005) in specific CME
activity questions included resolving
misconceptions related to multidisciplinary
team care approaches, knowledge of how to
individualize HbA1c targets, understanding the
need to initiate and intensify insulin therapy,
and increasing knowledge of appropriate
therapeutic options. While physicians
indicated adequate pre-activity knowledge in
the role of post-prandial hyperglycemia in
HbA1c control, performance outcomes
regarding appropriate initiation of prandial
insulin were improved by 56% (p\0.0005)
post-activity. In addition to positive
improvements in physician performance
outcomes, positive improvements in patient
health outcomes, as measured by this study,
were also observed. These patient health
outcomes were designed to measure level 6 of
Moore’s framework [2] for assessing CME
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program effectiveness, which evaluates the
degree to which the health status of patients
improves due to changes in the practice
behavior of physicians [2]. This study used the
reduction of mean HbA1C levels and additional
use of anti-diabetic medication as the main
endpoints for the evaluation of health
outcomes; however, the management of
diabetes may be multi-facet and may include
other elements, such as patient satisfaction,
etc., which were not evaluated in this study.
Improved patient health outcomes included a
significant reduction in mean HbA1c levels and


























Number of antihyperglycemic drugs
Mean 1.7
SD
Total patient count 264
BMI body mass index, HbA1c glycated hemoglobin, SD
standard deviation
Fig. 1 Change in mean HbA1c levels between baseline
and follow-up periods. HbA1c glycated hemoglobin
Table 4 Summary of patient health outcome results:
intra-individual baseline vs. follow-up comparison
Endpoint result N % Patients
HbA1c reduction C0.5% 170 64.4
Insulin therapy initiation 117 44.3
HbA1c B 7.0% 50 20.3
Therapy escalation 197 75
Total patient count 264
HbA1c glycated hemoglobin
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an intensification of therapy for a majority of
patients (75%) and insulin therapy initiation for
nearly half of the patient population (44.3%)
between the baseline and follow-up periods.
Reduction of elevated mean HbA1c levels
(target goal around 7%) is important in
potentially reducing morbidity and mortality
for T2DM patients. The intensification of
therapy and initiation of insulin therapy
observed for a large number of patients would
potentially be very beneficial to patient health
outcomes, including mean HbA1c levels.
Appropriate treatment regimens and
maintaining tight glycemic control are
important for preventing complications
associated with T2DM [1].
Several risks of bias are present in the study
design which may contribute to alternate
explanations for the improvements in patient
health outcomes. Primarily, it is unknown how
physicians selected the patients to include in this
study, and it is possible that patients who had the
greatest improvements were selectively chosen.
However, the patient chart forms consisted of 25
questions with themain endpoint of Hb1Ac level
embedded within these questions. In addition,
physicians were blinded to the specific outcomes
to be assessed. Therefore, deliberate selection of
patients demonstrating improvements in Hb1Ac
levels is not likely to have been a systematic
method of patient selection. The response rate
was low with only a small subset of physicians
participating in the multiple CME curricula and
completing patient chart reviews, and this could
have skewed the results. This low rate of
participation limits conclusions drawn on the
impact of the CME on physician performance
and improvements in patient health outcomes.
In addition, physicians that were more willing to
participate in this quality improvement study
may be more willing to change their practice
versus those that did not participate. Finally,
although considerable improvements in
knowledge occurred collectively, a direct
connection between CME results for individual
physician improvements and patient health
outcomes was not made. Some of these study
design limitations were due to resource
limitations that educators face in conducting
CME. However, despite these concerns, the data
support that CME can potentially have a
significant impact on clinician practice
outcomes. To confirm these results, future
studies should budget for randomized
controlled studies of multiple media, case-based
CMEs with a clear definition of intervention with
control groups, and measurements of
effectiveness at multiple points
post-intervention.
CONCLUSION
Preliminary results from this qualitative study
demonstrated potential for a positive
relationship between multi-dimensional
diabetes CME curricula and improvements in
measured patient health outcomes.
Improvements in patient health outcomes
included a significant reduction in HbA1c
levels, reduced barriers to the use of insulin,
and reduced clinical inertia in patients with
T2DM. These data suggest that CME which
addresses physician knowledge gaps can
potentially impact patient health outcomes.
Future studies are needed to establish a direct
link between individual physician
improvements and patient health outcomes
post-CME activities.
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